TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Sees Large Growth in Short Interest

TransCode Therapeutics, Inc. (NASDAQ:RNAZGet Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 89,600 shares, an increase of 71.0% from the December 15th total of 52,400 shares. Based on an average daily volume of 57,900 shares, the short-interest ratio is presently 1.5 days. Currently, 12.9% of the shares of the company are short sold.

Institutional Trading of TransCode Therapeutics

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management boosted its holdings in shares of TransCode Therapeutics, Inc. (NASDAQ:RNAZFree Report) by 149.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,138 shares of the company’s stock after purchasing an additional 30,000 shares during the period. Sheets Smith Wealth Management owned about 0.29% of TransCode Therapeutics worth $29,000 at the end of the most recent quarter.

Wall Street Analyst Weigh In

Separately, HC Wainwright lifted their price target on shares of TransCode Therapeutics from $3.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th.

Get Our Latest Stock Analysis on RNAZ

TransCode Therapeutics Stock Performance

Shares of NASDAQ RNAZ remained flat at $3.35 during mid-day trading on Friday. The company had a trading volume of 28,766 shares, compared to its average volume of 112,242. TransCode Therapeutics has a 52 week low of $2.66 and a 52 week high of $83.16. The company has a 50 day moving average price of $141.64 and a 200-day moving average price of $392.17.

TransCode Therapeutics Company Profile

(Get Free Report)

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.

Featured Stories

Receive News & Ratings for TransCode Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransCode Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.